Why Discontinue Jardiance (Empagliflozin) in Fournier's Gangrene
Jardiance (empagliflozin) must be discontinued immediately when Fournier's gangrene is suspected or confirmed, as continued SGLT2 inhibitor therapy during this life-threatening necrotizing infection can worsen outcomes and delay recovery. 1, 2, 3
Immediate Discontinuation is Mandatory
The FDA explicitly recommends discontinuation of SGLT2 inhibitors if Fournier's gangrene is suspected, particularly when patients present with pain, tenderness, erythema, or swelling in the genital or perineal area accompanied by fever or malaise. 2
The American Diabetes Association guidelines state that necrotizing fasciitis of the perineum (Fournier gangrene) is rare but requires prompt treatment if suspected, which includes stopping the SGLT2 inhibitor. 1
All published case reports consistently demonstrate that empagliflozin and other SGLT2 inhibitors were permanently discontinued upon diagnosis of Fournier's gangrene, with patients transitioned to alternative diabetes management (typically basal-bolus insulin regimens). 4, 5, 6, 7
Mechanistic Rationale for Discontinuation
SGLT2 inhibitors increase glycosuria, creating a glucose-rich environment in the genital area that promotes bacterial proliferation and mycotic infections, with genital mycotic infections occurring in 6% of SGLT2 users versus 1% with placebo. 3
The medication's mechanism directly contributes to the pathophysiologic environment that allows progression from simple genital infections to severe necrotizing fasciitis. 4, 8
Continued SGLT2 inhibitor use during active infection would perpetuate the glycosuric state that facilitates bacterial growth and tissue destruction. 5, 6
Clinical Context and Timing
Fournier's gangrene associated with SGLT2 inhibitors has been reported from 1 month to 6 years after drug initiation, with most cases occurring in patients with diabetes and additional risk factors. 8
The infection requires emergency surgical debridement, broad-spectrum antibiotics, and hemodynamic support—all of which necessitate cessation of the offending agent. 9, 10
Case reports document that patients often had preceding episodes of genital thrush or mycotic infections before developing Fournier's gangrene, suggesting a progression that could be halted by early drug discontinuation. 4
Post-Discontinuation Management
After discontinuation, patients require alternative glycemic management, typically with basal-bolus insulin regimens, to maintain glucose control during the acute illness and recovery period. 4, 5, 6
SGLT2 inhibitors should not be restarted after resolution of Fournier's gangrene due to the established association and risk of recurrence. 5, 8
The cardiovascular and renal benefits of SGLT2 inhibitors, while substantial in other contexts, are irrelevant during active life-threatening infection where mortality rates approach 20-50%. 9, 10